LLY

Outcome

—

Return

—

Status

—

Subscribe to read

Outcome

—

Return

—

Status

—

Subscribe to read

Outcome

–

Return

+0.83%

Status

scored

Trim 15-20% of LLY at market into current weakness (~$1,170) per binding 10/6 Underweight lesson that a 25-35% trim was over-calibrated, preserving 80-85% core through Q3 2025 earnings. Target weight 1.5%, max 1.5-2% until technical confirmation, hard stop $1,073 (200 SMA close). 50% of proceeds to cash for post-Q3 redeployment, 50% to XPH ETF to reduce single-name and GLP-1 class concentration.

Outcome

✗

Return

-1.61%

Status

scored

Maintain LLY at Hold given the tension between elite fundamental metrics (102% ROE, 54% operating margins, $11B FCF inflection) and stretched valuation (25x forward P/E requiring 60% EPS growth from a $65B base). Execute conditional Hold architecture: accumulate only at $1,150 or $1,113 on pullbacks, trim partial profits at $1,198-$1,206 on strength, hard stop at $1,073. Mandatory reassessment at Q3 2026 earnings and orforglipron Phase 3 readout.

Outcome

✗

Return

+2.70%

Status

scored

The Portfolio Manager trims 25-35% of LLY at market ($1,155-$1,170) while retaining 65-75% of the position, arguing that HOLD has bled alpha for three consecutive decisions while a full SELL would replay the over-calibrated 9/25 anti-pattern. The Underweight rating balances asymmetric Q3 2026 earnings risk against the intact structural compounding thesis (102% ROE, 54% OPM, supply-rationed GLP-1 demand), with proceeds split 50/50 between cash for post-Q3 optionality and a diversified pharma basket (XPH ETF) to reduce single-name concentration.

Outcome

✗

Return

+1.26%

Status

scored

Maintain LLY core position (85-90%) while executing a 10-15% tactical trim at market (~$1,107) into current weakness per binding lessons from prior reflections, with hard stop at $1,071 close (200 SMA structural break). Re-entry requires either a confirmed close above $1,170 on volume >3.5M with MACD line cross, or Q3 2026 earnings validating the $47.59 forward EPS trajectory with reaffirmed 47%+ revenue growth. Optional Dec 2026 $1,100/$1,000 put spread hedge (~3-4% notional) addresses multiple-compression tail risk.

Outcome

✓

Return

+0.02%

Status

scored

Maintain LLY as a Hold with a mandated 10-15% tactical trim at market (~$1,150) to honor the binding 9/30 and 10/1 reflections, while preserving 85-88% core through the Q3 2026 earnings catalyst. Hard stop is $1,065 (200 SMA structural break), with simple OR-logic re-entry at $1,170+ on volume >3.5M with MACD bullish cross, OR pullback to $1,070-1,090 with stabilization. Optional Dec 2026 $1,100/$1,000 put spread provides tail protection.

Outcome

✓

Return

-0.61%

Status

scored

Maintain core LLY position (85-90%) while executing a 10-15% tactical trim into the $1,170-$1,200 resistance zone to address asymmetric macro risk, with a hard stop at $1,065 (200 SMA structural break) and simple re-entry triggers (breakout above $1,170 on volume >3.5M, or Q3 2026 earnings validating $47.34 forward EPS); optional Dec 2026 $1,100/$1,000 put-spread hedge for concentrated exposure.

Outcome

✓

Return

-0.62%

Status

scored

Maintain LLY at ~$1,157 with no new capital deployment pending technical resolution; trim 20-25% into any failed test of $1,175-$1,180 resistance zone, while adding half-size on close below $1,070 with MACD divergence or 1/3-size on pullback to $1,140-$1,150 with RSI>40. Hard stop at $1,000 close; mandatory reassessment at Q3 2026 earnings (late October).

Outcome

✓

Return

-2.33%

Status

scored

Maintain a calibrated Underweight on LLY by trimming 15-20% of the position into the $1,196-$1,230 resistance zone while preserving an 80-85% core holding for the structural compounding thesis and Q3 earnings catalyst. Hard stop is set at $1,065 (200 SMA close), with a single re-entry trigger requiring either a confirmed close above $1,230 on volume exceeding 3.5 million, or a capitulation pullback to $1,070-$1,090 with stabilization—not both per prior lessons.

Outcome

✓

Return

-0.01%

Status

scored

Maintain core LLY position at the 4-5% portfolio cap with no fresh capital deployment at $1,185; the Overweight sizing target remains the destination but current entry-zone risk/reward (1.2:1 at upper Bollinger resistance) does not warrant action. Two explicit add triggers will execute the overweight path: a pullback to $1,150-$1,165 (50 SMA confluence, RSI>45) or a confirmed daily close above $1,230 on volume >3.5M, each with 1.5-2% sizing. Mandatory tactical reassessment at Q3 2026 earnings.

Outcome

✗

Return

+0.11%

Status

scored

Recommend trimming 30-35% of LLY position at the upper Bollinger band zone ($1,183-$1,210), harvesting gains from stretched valuation (39.7x trailing P/E with 59% required forward EPS growth). Preserve 65-70% core position for the structural compounding thesis with a hard stop at $1,067 (200 SMA close), and employ a scaled three-vector reload architecture targeting $1,130-$1,150, $1,067-$1,090, and sub-$1,067 volatility opportunities. Mandatory reassessment at Q3 2026 earnings.

Outcome

✓

Return

+0.13%

Status

scored

Maintain LLY at Hold with trigger architecture calibrated to the 39x trailing / 25x forward valuation tension and incomplete technical confirmation. Do NOT add at current price — the 50 SMA reclaim on below-average volume with still-negative MACD (-6.92) constitutes a test, not a breakout. Two executable add triggers: confirmed daily close above $1,200 on volume >3.5M, or pullback to $1,151 with RSI holding >40, each scaling in 3-4% of portfolio.

Outcome

✗

Return

+2.68%

Status

scored

Maintain core LLY position at HOLD with a single explicit add trigger requiring daily close above $1,175 (50 SMA) on volume plus MACD line crossing above signal, with meaningful 1.5-2% portfolio sizing rather than token adjustments. Mandatory mid-horizon reassessment at Q3 2026 earnings (late October) addresses the prior pattern of zero executions from over-engineered trigger architectures.

Outcome

✗

Return

-1.64%

Status

scored

Analysts unanimously maintain HOLD for LLY based on converging quality metrics (102% ROE, 54.2% operating margins, $11.07B TTM FCF) and structural demand (700K Medicare starts with 70% on Lilly drugs), while respecting tactical headwinds including the 39× trailing P/E, declining 50 SMA resistance at $1,175.88, and pre-Q3 earnings binary risk. The position architecture calls for modest sizing with a hard stop at $1,095 and an add trigger at confirmed close above $1,176.

Outcome

–

Return

+0.45%

Status

scored

Initiate Overweight on LLY at $1,130-$1,160 zone with 3-3.5% Tranche 1 allocation based on RSI>50 confirmation (already met at 51) and MACD histogram positive flip, despite unresolved leverage overhang ($46B net debt) and binary Q3 earnings risk ahead. Stop set at $1,090 (1.5x ATR buffer), with Tranche 2 reserved for confirmed 50 SMA reclaim at $1,176 with MACD line cross and volume, and Tranche 3 for post-Q3 earnings or defended $1,063 test with positive divergence.

Outcome

✓

Return

+1.04%

Status

scored

Adopt an Overweight rating on LLY with deferred Tranche 1 entry of 3-3.5% of portfolio in the $1,130-$1,160 zone conditional on price holding through the Trump pharma remarks catalyst without breaking $1,130; place hard stop at $1,090. The structural thesis is intact with elite-tier fundamentals (54.2% operating margins, 102.3% ROE, $11.07B TTM FCF) and compressed forward P/E at 24.35x, but timing requires confirmation that the 50 SMA at $1,176 has not been reclaimed and the Trump headline cycle has cleared. Reserve Tranche 2 (1.5-2% add at $1,176 50 SMA reclaim with volume) and Tranche 3 (1-1.5% reserve at $1,063 capitulation test) for subsequent staged execution.

Outcome

✓

Return

+0.04%

Status

scored

Maintain LLY at neutral weight with a single tactical add trigger rather than perpetual passive patience. The add trigger requires confirmed MACD bullish cross (line above signal at -13.15) AND daily close above 10 EMA ($1,143) AND volume turning the declining VWMA back up — all simultaneously. Keep the 60-70% sizing cap as the ceiling and $1,063 stop (200 SMA) as the structural floor, with full reassessment at Q3 2026 earnings in late October as the binary catalyst that will resolve the current setup.

Outcome

✓

Return

+1.28%

Status

scored

Maintain LLY at neutral weight with a 5-10% trim into the $1,135-$1,145 zone and a hard stop at $1,050. Scale into a two-tranche add at $1,063 — half on a defended test of the 200 SMA, half on a confirmed close above the 10 EMA with improving MACD. HOLD rating reflects structural-compounder fundamentals (FCF inflected to $11.07B TTM, 102% ROE, 83% gross margins) balanced against broken technical momentum, hawkish macro, and stacked binary catalysts (EASD late September, Q3 earnings mid-October). Price target is $1,260 on a 12-18 month horizon contingent on Q3 reacceleration.

Outcome

✓

Return

+0.15%

Status

scored

Maintain LLY at neutral weight with a tiered execution framework rather than plain-vanilla hold. Three explicit add triggers are defined post-catalyst (Tier-1: 10 EMA reclaim with RSI>50 post-FOMC; Tier-2: 50 SMA reclaim with RSI>55; Tier-3: constructive retatrutide data), paired with hard stop at $1,115 and exit trigger at $1,062 on 200 SMA break. A 5% defensive trim is recommended into binary catalysts, with mandatory reassessment after FOMC and EU retatrutide readout.

Outcome

–

Return

-0.19%

Status

scored

Analysts resolve to Overweight LLY with 25-30% initial position, deploying less than the Aggressive Analyst's 40-50% but more than the Conservative Analyst's cash stance. The thesis rests on 102% ROE, 54% operating margins, revenue tripling to $79.7B, and Morgan Stanley's downgrade of NVO confirming competitive shift toward LLY, while respecting deteriorating momentum (6-session MACD bearish cross, histogram expanding from -5.67 to -7.72) and 38x trailing P/E with zero rate-cut support eroding. Staged entry allows capturing structural conviction while honoring timing concerns, with hard stop at $1,055 and tiered add-on triggers requiring both price and momentum confirmation.

Outcome

✗

Return

+2.02%

Status

scored

Underweight LLY with a 20% trim executed in two tranches (10-12% at current levels $1,115-$1,120 and 8-10% on any relief bounce toward $1,145 or $1,183), preserving participation in the structurally intact compounder while locking in gains from the 56% twelve-month rally. Hard trailing stop on residual core at $1,072 close with full exit trigger below $1,062 (200 SMA), calibrated between the Conservative's too-tight $1,085 and the Aggressive's too-loose $1,052 stop to avoid whipsaw given the elevated ATR of $31.76.

Outcome

✓

Return

-0.65%

Status

scored

Maintain Hold on LLY with a tiered scale-in framework rather than pure passive positioning or aggressive accumulation. The fundamental thesis (47.7% revenue growth, 54% operating margins, $11B FCF) is too strong for Underweight, but the lack of confirmation signals (expanding negative MACD at -10.43, sub-45 RSI, broken 200 SMA trend) prevents an Overweight rating. Deploy capital in three tranches: Tier-1 at $1,094 on MACD contraction or RSI>45, Tier-2 at $1,070-$1,090 on reversal confirmation, and Tier-3 at $1,020-$1,040 only on capitulation.

Outcome

–

Return

-0.11%

Status

scored

Initiate Overweight on a generational compounder (47.7% revenue growth, 54% operating margins, 102% ROE, $11B FCF) via a three-tranche scaling-in architecture after a 12% pullback from $1,280, deploying 20% at current $1,118-$1,128 levels with a confirmation gate (lower Bollinger hold + MACD contraction or RSI>45), reserving 40% for the $1,103 lower Bollinger zone and 40% for the $1,061 200 SMA test, with a hard stop at $1,050.

Outcome

✗

Return

+0.03%

Status

scored

Ratify the Research Manager's Underweight rating and trim 25-35% of LLY exposure, executing 15-20% immediately at current levels (~$1,155-$1,170) and 10-15% contingently on any relief bounce toward $1,165-$1,189. Hard stop residual at $1,061 close (200 SMA). Do not initiate new positions; re-entry preferred at $1,020-$1,040 (flush) or $1,070-$1,090 (200 SMA zone) with confirmed MACD contraction and RSI>45. First tactical checkpoint is Q3 2026 earnings (late October/early November).

Outcome

✓

Return

-2.21%

Status

scored

Trim 15-20% of LLY position in tranches due to confirmed technical deterioration across multiple timeframes (MACD expanded from +21.81 to -9.62, RSI 41), stretched valuation (38.6x trailing P/E, 24.3x forward P/E), and accelerating risk vectors including Trump drug pricing expansion (17→26 companies) and five competitive programs; maintain core 80-85% through Q3 2026 earnings binary catalyst (~6-7 weeks out) to resolve balance sheet yellow flags.

Outcome

–

Return

-0.88%

Status

scored

Trim 10-15% of LLY immediately at $1,155-$1,170 given broken 50-SMA, MACD at -9.98 with 7 consecutive negative sessions, and RSI at 43.37; maintain ~85-90% core through Q3 2026 earnings with volatility stop at $1,100 and structural exit only below $1,059 on >4M volume. Tiered re-entry zones at $1,070-$1,090 (200-SMA), $1,020-$1,040 (flush add), and MACD contraction to -5.00 with RSI>45 for tier-1 re-engagement.

Outcome

✓

Return

-0.04%

Status

scored

Maintain core LLY exposure with HOLD rating—the structural thesis (30.5% revenue growth, 54% operating margins, 102% ROE) remains intact, but the technical setup is materially worse than the August Overweight call (MACD histogram -9.98 and expanding vs -7.60 at prior call). Stage adds at $1,070–$1,090 (primary) and $1,020–$1,040 (secondary), with a new Tier-1 starter permitting 10–15% of intended add on MACD flattening toward zero per the September lesson. Hard stop at $1,000 close; Q3 2026 earnings is the binary catalyst for balance sheet resolution.

Outcome

✓

Return

+0.01%

Status

scored

Maintain HOLD at $1,160 with active-sizing discipline—do not add at current levels due to technical deterioration (MACD bearish, RSI 43.6, price below key moving averages) but do not aggressively trim ahead of the ~6-week Q3 earnings binary catalyst. Tiered re-entry zones at $1,100-$1,125 (primary) and $1,050-$1,090 (secondary at 200 SMA), with stops tightened to $1,080 or hard exit at $1,050 on rising volume.

Outcome

✓

Return

+0.28%

Status

scored

Initiate Overweight at $1,150 with disciplined scale-in, deploying 33-40% of target allocation now while capping the position at 2% of portfolio, reserving 60-67% for future entry on 200 SMA retest at $1,056 with MACD confirmation or 50 SMA reclaim with volume and RSI filters; hard exit set at close below $1,070 on >4M shares, avoiding chasing above $1,250 without technical reset.

Outcome

✓

Return

-1.52%

Status

scored

The decision ratifies Underweight on LLY based on three confirming technical breakdowns, sequential EPS deceleration (Q1 2026 $8.26 → Q2 2026 $7.94), and extreme valuation (39.5x trailing, 24.9x forward P/E embedding 59% EPS growth with zero margin for disappointment). The action is a calibrated 30% trim staged in tranches at current levels and $1,200-$1,215 retest, with 3-month protective puts on the residual and a hard stop at $1,155 — NOT a thesis rejection of the generational compounder, but active risk reduction ahead of a potential 200 SMA retest at $1,056 or Q3 2026 earnings catalyst.

Outcome

✓

Return

-0.13%

Status

scored

Ratify HOLD with active sizing discipline—three risk analysts converge on HOLD given intact secular trend (200 SMA at $1,055 providing 10% downside cushion, 48% revenue growth, 54% operating margins, 102% ROE) despite broken momentum (50 SMA breach, MACD at -4.12, RSI collapsed from 74.67 to 45.81) at >40x trailing / 24.9x forward P/E. Convert passive HOLD to active mandate: trim 10-15% if position exceeds benchmark weight, tighten stop to $1,080, and defer adds to tiered levels at $1,113 or $1,055 with technical confirmation. Q3 earnings (late October) is the binary catalyst for rating revision.

Outcome

–

Return

-1.12%

Status

scored

Trim 30% of LLY via staged execution (15% at current $1,189, 15% on retest of $1,215-$1,235 resistance zone) targeting 70% benchmark weight, with hard stop at $1,148 on 50 SMA breakdown. Re-entry requires multi-day confirmation above $1,224 with MACD bullish re-cross and RSI >50 — a single close is insufficient in this volatility regime.

Outcome

✓

Return

-3.59%

Status

scored

Portfolio managers are trimming 30% of LLY via a two-tranche staged execution (15% now at $1,230-$1,240, 15% on retest of $1,260-$1,280), citing bearish technical signals (RSI divergence, MACD compression, failed 08-19 breakout), extreme valuation at 32.5x P/B and $1.1T market cap, and balance-sheet deterioration ($8.86B debt issuance). A tiered stop-loss framework tightens exposure at $1,200 closes and exits fully at $1,182 closes, while re-entry requires either a pullback to the $1,180-$1,200 zone with reversal confirmation or a confirmed close above $1,292 on volume exceeding 4M shares.

Outcome

✓

Return

-1.06%

Status

scored

LLY maintained at HOLD with 1.5-2% portfolio weight (down from prior 2-3% cap) based on premium valuation at 41.9x trailing earnings, flat H1 2026 FCF against +29% net income growth, and 18-month net debt increase from $35B to $46B. No fresh entry at current ~$1,247 levels—tiered re-entry zones established at $1,180 (50 SMA), $1,100, and $1,050 (200 SMA), with hard thesis-break stop at $1,050 closing basis.

Outcome

✓

Return

-0.67%

Status

scored

Three-way analyst convergence on HOLD ($1,255) is decisive; maintain existing core position given intact fundamentals (91% Mounjaro growth, 102% ROE, 54% operating margins, Foundayo launched, GLP-1 moat widening) but upgrade to active trim-to-benchmark discipline per the binding 2026-08-19 lesson. Stage new adds only at $1,200-$1,225 pullback zone (10 EMA/VWMA/June breakout confluence) capped at 5% NAV per tranche; the Aggressive's 7-10% sizing push is rejected due to 42x trailing P/E concentration risk and rising leverage (net debt +51% to $46B). Hard stop at $1,170 close; binary catalyst for rating revision is H2 2026 FCF trajectory vs H1 flat-line baseline.

Outcome

✓

Return

+0.88%

Status

scored

Maintain existing LLY position at benchmark weight with explicit trim-to-benchmark discipline if above weight; do not chase at current $1,244 levels. Tier 1 add zone is $1,176-$1,194 (50 SMA/VWAP confluence) capped at 1.2x benchmark until IRA MFN pricing clarity emerges, with hard stop at $1,176 on closing basis. H2 2026 FCF inflection and Q3 2026 earnings are the binary catalysts for rating revision.

Outcome

✗

Return

-2.81%

Status

scored

HOLD rating maintained despite elite fundamentals (47.7% YoY revenue growth, 102% ROE, $11B FCF) because current valuation (27x forward earnings, 22.4% above 200 SMA) offers insufficient risk-adjusted expected return; tactical 10-15% trim recommended into $1,260-$1,300 zone to harvest volatility premium while preserving core position for the $1,150/$1,050 pullback add opportunity.

Outcome

✗

Return

+4.46%

Status

scored

Hold rating maintained as the trader's own prerequisites (primary filing confirmation, moving average validation, volume confirmation, guidance review, cash flow/debt checks, oral-GLP-1 launch confirmation) have not been satisfied. The preferred entry is a pullback to $1,196-$1,205 or a confirmed close above $1,250 on at least 4M shares; if a starter is authorized, reduce to 1/4 of intended weight (~0.31x normal weight) rather than the planned 1/3. Position capped at 5% NAV with tactical reassessment tied to H2 FCF inflection, Q3 2026 earnings, or technical invalidation triggers.

Outcome

✗

Return

+3.60%

Status

scored

Three-way analyst consensus converged on HOLD for LLY at $1,183, citing exceptional fundamentals (102% ROE, 910bps margin expansion, GLP-1 moat) but zero valuation margin of safety at 39.8x TTM P/E. The framework converts HOLD into executable alpha via tiered entry triggers: Tier-1 prioritizes pullback to $1,150-$1,167 (rising 50 SMA) over breakout, while Tier-2 requires confirmed close >$1,225 on volume >3.5M shares. H2 FCF acceleration serves as the binary catalyst for next rating revision.

Outcome

✓

Return

+0.25%

Status

scored

Maintain the 3-5% LLY position unchanged at $1,209 — the same price level where the 2026-08-13 Buy produced -2.4% raw return and -2.2% alpha versus SPY due to aligned distribution signature, 25x forward P/E premium, and stretched price within 4% of 52-week high after a 91% rally. The bull case (Foundayo UK approval, 47.7% YoY revenue growth, 102% ROE, dominant GLP-1 moat) is genuinely compelling but the asymmetric downside (25-40% on GLP-1 event) materially exceeds limited upside at this valuation, justifying disciplined stair-step triggers rather than front-loaded addition.

Outcome

✓

Return

-2.39%

Status

scored

The portfolio manager recommends reducing the LLY position by 25% over 3-5 sessions, targeting 60-75% of benchmark weight, due to stretched valuation at 40.6x trailing earnings requiring 58% EPS growth just to maintain price, combined with poor risk asymmetry (7-15% upside vs 14-30% downside). The remaining 75% core position is protected by a multi-factor trend-risk stop at $1,167 (50 SMA) on volume + MACD cross + RSI<45, with hard exit at $1,040 (200 SMA), and four pre-committed re-entry tiers ranging from $1,182-$1,196 demand zone to confirmed breakouts above $1,247 to prevent passive Underweight drift.

Outcome

✓

Return

-0.92%

Status

scored

Maintain LLY at current weight with HOLD rating; fundamentals (47.7% YoY revenue growth, 54.2% operating margins, 102.3% ROE, GLP-1 moat) support existing position but 41x trailing PE, two 7% pullbacks in six weeks, and $12.5B debt increase argue against adding capital at $1,220. Execute pre-committed triggers: half-size add on $1,244 breakout above 1.5M volume, full-size add on pullback to $1,164 50 SMA or $1,115 lower Bollinger; hard stop at $1,150, no hedging.

Outcome

✓

Return

+0.43%

Status

scored

Maintain LLY at Hold with $1,260 price target and 12-18 month horizon. Do not add at current $1,215 — the 26.10x forward P/E × $46.56 EPS = $1,214 fair value leaves zero margin of safety for incremental capital. Use a two-tier entry: half position at $1,150 on first test of lower Bollinger/10 EMA confluence, second half at $1,115–$1,125 on confirmed 50 SMA touch. Post-CPI weakness is the appropriate trigger, not pre-CPI. Cap any trim at 5–10% at $1,239 to avoid repeating the 2026-08-04 alpha-destruction error. Exit on daily close below $1,036 (200 SMA); trim decisively if close below $1,161 (50 SMA) on volume. Address the 98% single-name concentration through portfolio rotation into complementary healthcare or index hedge, not through LLY-specific selling.

Outcome

✓

Return

-1.37%

Status

scored

Maintain LLY at current weight with a Hold rating as the $1,238 June swing high test remains unresolved and 26.5x forward P/E offers no margin of safety. Pre-committed add tiers target pullbacks to $1,160 (2% allocation, stop $1,109), $1,109 (2%, stop $1,050), or a confirmation-based breakout above $1,238 on volume >3.5M shares (1% starter, stop at breakout day's low).

Outcome

✗

Return

+3.90%

Status

scored

Maintain Eli Lilly at current weight without adding at $1,186 or trimming aggressively. Execute via 33-40% scale-in tranches (not the aggressive 50% or conservative 25-30%) at $1,100-$1,125 with $1,090 hard stop for first tranche and $1,031-$1,050 reserved for confirmed 200 SMA touch. No derivative overlays; use mechanical MA-based invalidation (close below $1,157 on volume breaks medium-term thesis, below $1,031 breaks long-term thesis). Q3 2026 earnings is the binary catalyst.

Outcome

✓

Return

-0.52%

Status

scored

Maintain LLY at Hold as the setup remains constructive but technically unconfirmed; dual-confirmation triggers ($1,225 close + positive MACD histogram) are required before adding, with a hard stop at $1,155. The investment thesis balances exceptional fundamental execution (+91% Mounjaro growth, second guidance raise to $85–87B, 107% ROE) against extended valuation (25.8x forward P/E) and unconfirmed technicals, with prior lesson track record dictating patience over aggression. Reassess at next earnings print or upon technical resolution.